Vessel dilator and kaliuretic peptide inhibit ras in human prostate cancer cells

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 971-976

  Sun, Ying ^a   Eichelbaum, Ehrentraud J ^a   Skelton IV, William P ^a   Lenz, Anne ^a   Hai, Wang ^a   Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cardiac hormones; Kaliuretic peptide; Prostate cancer; Ras; Vessel dilator

Indexed keywords

CYCLIC GMP; KALIURETIC PROTEIN; PEPTIDE HORMONE; RAS PROTEIN; UNCLASSIFIED DRUG; VESSEL DILATOR;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN PHOSPHORYLATION;

ADENOCARCINOMA; AGED; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUANOSINE DIPHOSPHATE; HUMANS; IMMUNOBLOTTING; MALE; NATRIURESIS; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; RAS PROTEINS; SODIUM-POTASSIUM-EXCHANGING ATPASE; TUMOR CELLS, CULTURED;

EID: 64949135331     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Scholl FA, Dumesic PA and Khavari PA: Effects of active MEK 1 expression in vivo. Cancer Lett 230: 1-5, 2005.
2. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong. EWT, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangeliste C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007.
3. Sebolt-Leopold JS: Advances in the development of cancer therapeutics directed against the Ras mitogen-activated protein kinase pathway. Clin Can Res 14: 3651-3656, 2008.
4. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT and Steelman LS: Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 9: 614-630, 2008.
5. Sebolt-Leopold JS and Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Rev Cancer 4: 937- 947, 2004.
6. Roberts PJ and Der CJ: Targeting the RAF-MEK-ERK mitogen- activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
7. Vesely DL, Eichelbaum EJ, Sun Y, Alii AA, Vesely BA, Luther SL and Gower WR Jr: Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 27:445-452, 2007.
8. Vesely DL, Vesely BA, Eichelbaum EJ, Sun Y, Alli AA and Gower WR Jr: Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. In Vivo 21: 973-978, 2007.
9. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 27: 1387-1392, 2007.
10. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 26: 3217-3222, 2006.
11. Waldman SA, Rapoport RM and Murad F: Atrial natriuretic factor selectively activates membranous guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 259: 14332-14334, 1984.
12. Vesely DL: Signal transduction: Activation of guanylate cyclase- cyclic guanosine-3'-5' monophosphate system by hormones and free radicals. Am J Med Sci 314: 311-323, 1997.
13. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer 27: 274-281, 1978.
14. deRooij J and Bos JL: Minimal Ras-binding domain of Rafl can be used as an activation-specific probe of Ras. Oncogene 14: 623- 625, 1997.
15. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.
16. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Insulin and epidermal growth factor activation of ERK 1/2 and DNA synthesis is inhibited by four cardiac hormones. J Cancer Mol 3(4): 113-120, 2007.
17. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Cardiac hormones activate ERK 1/2 kinases in human fibroblasts. Horm Metab Res 41: in press, 2009.
18. Vesely BA, Alii AA, Song S, Gower WR Jr, Sanchez-Ramos J and Vesely DL: Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 35: 700-710, 2005.